MODERN IMMUNOHISTOCHEMISTRY
|
|
|
- Julianna Sabrina Brooks
- 8 years ago
- Views:
Transcription
1 MODERN IMMUNOHISTOCHEMISTRY Cambridge Illustrated Surgical Pathology Peiguo G. Chu City of Hope National Medical Center, Duarte, California Lawrence M. Weiss City of Hope National Medical Center, Duarte, California CAMBRIDGE UNIVERSITY PRESS
2 1. Modern Tumor Immunohistochemistry 1 Introduction 1 Quality Assurance and Certification 2 Tissue Preparation 2 E p i t o p e R e t r i e v a l Controls ' ' 3 Antibodies.. 3 Unwanted Immunostaining 9 2. Skin Tumors 11 Melanocytic Tumors 11 Melanocytic Markers 14 Adnexal Tumors 24 Epidermal Tumors 31 Paget Disease Tumors of Head and Neck 52 Tumors of Salivary Gland 52 Salivary Gland Tumors with Dual Luminal- Myoepithelial/Basal Cell Differentiation 52 Salivary Gland Tumors with a Single Line Differentiation 64 Tumors of the Nasal Cavity and Paranasal Sinuses Tumors of the Lung and Mediastinum 88 Tumors of the Lung 88 Immunohistochemical Markers of Lung Tumors 88 Different Types of Lung Tumors 90 Tumors of the Mediastinum 101 Tumors of the Pleura 108 Mesothelioma-Associated Markers 121 Adenocarcinoma-Associated Markers Tumors of the Endocrine System 137 Immunohistochemical Markers of Neuroendocrine Differentiation 138 Immunohistochemistry of Endocrine Organs 142
3 Pituitary Gland 142 Adrenal Gland 147 Paraganglia 151 Thyroid Gland 153 Parathyroid Gland 158 Endocrine Lung 159 Gastrointestinal Endocrine System 164 Endocrine Pancreas 168 Merkel Cells and Merkel Cell Carcinoma Tumors of the Digestive System 188 Esophagus 189 Squamous Cell Carcinoma 189 Intestinal Metaplasia 189 Esophageal Adenocarcinoma 193 Stomach 193 Gastric IM/Gastric Adenocarcinoma 193 Gastric Intraepithelial Dysplasia 195 Intestinal Type of Gastric Adenocarcinoma 197 Diffuse Type of Gastric Adenocarcinoma 199 Gastrointestinal Stromal Tumor 203 Duodenum and Small Bowel 209 Colon, Appendix, and Rectum 211 Colon Immunohistochemical Markers 211 Colo rectal Signet-Ring Cell Carcinoma 216 Pancreas 216 Pancreatic Ductal Carcinoma 221 Adenocarcinoma of Ampulla of Vater 227 Mucinous Cystic Neoplasms 228 Solid Pseudopapillary Neoplasm 233 Serous Cystic Neoplasms 238 Pancreatoblastoma 241 Acinar Cell Carcinoma 242 Mixed Exocrine-Endocrine Tumors 242 Liver. 244 Hepatocellular Carcinoma 244 Benign Bile Duct Proliferations (Bile Duct Adenoma and Hamartoma) and Bile Duct Carcinomas (Intrahepatic Cholangiocarcinoma and Extrahepatic Bile Duct Carcinoma) 254
4 7. Tumors of the Genitourinary System 270 Tumors of the Prostate 270 Metastatic Prostate Carcinoma Versus Nonprostate Carcinoma 270 Prostate Specific Markers 271 Differential Diagnosis of Primary Prostate Adenocarcinoma 273 Tumors of the Kidney 290 Markers for Renal Cell Carcinoma 292 Immunohistochemical Diagnosis of Renal Cell Carcinoma 304 Tumors of the Urinary Bladder 311 Urethelial Lesions 311 Adenocarcinoma 316 Spindle Cell Tumors 320 Tumors of the Testis 321 Germ Cell Tumors (GCTs) 321 Non Germ Cell Tumors Tumors of the Breast and Female Genital Organs 357 Tumors of the Breast 357 Breast Prognostic Markers 357 Metastatic Breast Adenocarcinoma Versus Metastatic Nonbreast Adenocarcinoma 363 Breast-Specific Markers 364 Metaplastic Carcinoma Versus Breast Spindle Cell Tumors 370 Intraductal Versus Invasine Ductal Carcinoma 372 Myoepithelial Markers 375 Intraductal Papillary Neoplasms 381 Ductal Versus Lobula Carcinoma 383 Basal-Like Carcinoma 385 Tumors of the Vulva, Vagina, and Cervix 387 Tumors of the Uterus 395 Uterine Glandular Lesions 395 Uterine Spindle Cell Lesions, 403 Gestational Trophoblastic Tumors (GTT) 406 Ovarian Tumors 418 Epithelial Tumors 418 Sex Cord-Stromal Tumors 434 Ovarian Stromal Tumors 442 Small Cell Carcinoma 450
5 9. Hematopoietic Tumors 472 Panleukocyte Antibody 473 B-Lineage Antibodies 476 Hodgkin Antibodies 482 T-/NK-Lineage Antibodies 484 Other Lymphoid Markers 489 Myeloid Markers 499 Histiocytic and Dendritic Antibodies 503 Mast Cell Antibodies 506 Epithelial Antibodies 506 Proliferation Antibodies 507 Applications of Immunohistochemistry to the Diagnosis of Malignant Lymphoma 508 Diagnosis of Malignant Lymphoma Versus Other Neoplasms 508 Diagnosis of Malignant Lymphoma Versus Reactive Lymphoid Hyperplasia 508 Subtypes of B-Cell Lymphoma 512 Subtypes of T-Cell Lymphoma 518 Immunophenotyping of Acute Leukemias, Myelodysplasia, and Myeloproliferative Disorders 522 Acute Leukemia in General 523 Acute Myeloid Leukemia 523 Acute Biphenotypic Leukemia 524 Myelodysplasia and Myeloproliferative Disorders 524 Histiocytic and Dendritic Neoplasms 524 Histiocytic Sarcoma 524 Langerhans Cell Histiocytosis (LCH) 525 Rosai-Dorfman Disease 525 Interdigitating Dendritic Cell Tumors 525 Follicular Dendritic Cells and Their Corresponding Tumors 525 Mast Cell Neoplasms Tumors of Soft Tissue and Bone 549 Epithelial Markers 551 Muscle Markers 552 Endothelial/Vascular Markers 561 Neural/Nerve Sheath Markers 563 Osteoblastic Markers 566 Other Markers Used in the Diagnosis of Soft Tissue and Bone Tumors 567 Immunohistochemistry of Soft Tissue Tumors, 574
6 Spindle Cell Soft Tissue Tumors Fibrosarcoma Leiomyosarcoma Neurofibroma Schwannoma Perineurioma Malignant Peripheral Nerve Sheath Tumor Synovial Sarcoma Solitary Fibrous Tumor Low-Grade Myofibroblastic Sarcoma Desmoid-Type Fibromatosis Dermatofibrosarcoma Protuberans Spindle Cell Rhabdomyosarcoma Inflammatory Myofibroblastic Tumor Myxoid Soft Tissue Tumors Myxoid Liposarcoma Myxoid Leiomyosarcoma Myxofibrosarcoma Low-Grade Fibromyxoid Sarcoma Myxoid Neurofibroma Myxoid Malignant Peripheral Nerve Sheath Tumor Myxoid Synovial Sarcoma Myxoid Solitary Fibrous Tumor Myxoma Nerve Sheath Myxoma Neurothekeoma Aggressive Angiomyxoma Superficial Angiomyxoma Ossifying Fibromyxoid Tumor Myxoinflammatory Fibroblastic Sarcoma Extraskeletal Myxoid Chondrosarcoma Epithelioid Soft Tissue Tumors Epithelioid Sarcoma Epithelioid Hemangioendothelioma Epithelioid Sarcoma-Like Hemangioendothelioma Epithelioid Angiosarcoma Benign Epithelioid Peripheral Nerve Sheath Tumor Epithelioid Malignant Peripheral Nerve Sheath Tumor Epithelioid Leiomyosarcoma Sclerosing Epithelioid Fibrosarcoma Extrarenal Rhabdoid Tumor Myoepithelial Tumors
7 Alveolar Soft Part Sarcoma 600 Clear Cell Sarcoma 600 PEComa 602 Pleomorphic Soft Tissue Tumors 602 Pleomorphic Liposarcoma 602 Pleomorphic Rhabdomyosarcoma 602 Pleomorphic Leiomyosarcoma 602 Pleomorphic Malignant Fibrous Histiocytoma 604 Small Round Cell Soft Tissue Tumors 604 Ewing Sarcoma/Primitive Neuroectodermal Tumor 604 Rhabdomyosarcoma 606 Desmoplastic Small Round Cell Tumor 607 Poorly Differentiated Synovial Sarcoma 607 Neuroblastoma 608 Immunohistochemistry of Bone Tumors 610 Conventional Osteosarcoma 610 Clear Cell Chondrosarcoma 610 Chondroblastoma 610 Adamantinoma 611 Chordoma 611 Small Round Cell Bone Tumors 611 Small Cell Osteosarcoma 615 Mesenchymal Chondrosarcoma Tumors of the Central Nervous System 634 Tumors of Neuroepithelial Tissue 634 CNS Tumor Markers 634 Immunohistochemistry of CNS Tumors 639 Tumors of the Sellar Region Metastatic Carcinoma of Unknown Primary 669 Common Sites of Metastatic Carcinoma of Unknown Primary (CUP) 669 Common Immunohistochemical Markers of CUPs 676 Common Types of CUPs 682 Index 689
Index. F Factor VIII-related antigen, see VWF FactorXIIIa, for dermatofibroma, 272-275 5-HT, see Serotonin
A Acantholytic squamous cell carcinoma vs epithelioid angiosarcoma, 56-57 Acinic cell carcinoma of pancreas, 76-77 vs ductal adenocarcinoma, 74-75 vs islet cell tumor, 78-81 Adenomatoid tumor vs hemangioma,
Contents. 1. Introduction and Approach to Fine Needle Aspiration Cytology... 1. 2. Head, Neck, Orbit and Salivary Glands... 12
Contents 1. Introduction and Approach to Fine Needle Aspiration Cytology... 1 Complications 1 Fine Needle Aspiration Technique 1 Evaluation of FNAC Smear 4 Cell Morphology 4 Nucleus 4 Cytoplasm 6 Background
Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach
Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach Publishing Team Erik Tanck (production manager/designer) Joshua Weikersheimer (publisher) Copyright 2006 by the American Society
Immunohistochemistry of soft tissue tumors
Immunohistochemistry of soft tissue tumors Immunohistochemistry Major advances : antigen retrieval techniques (HIER) sensitive detection systems numerous antibodies of good quality Standardization : automated
Immunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.
Disorders of Growth Introduction: Tumor Swelling / new growth / mass Two types of growth disorders: Non-Neoplastic Secondary / adaptation due to other cause. Neoplastic. Primary growth abnormality. Non-Neoplastic
Chapter I Overview Chapter Contents
Chapter I Overview Chapter Contents Table Number Contents I-1 Estimated New Cancer Cases and Deaths for 2005 I-2 53-Year Trends in US Cancer Death Rates I-3 Summary of Changes in Cancer Incidence and Mortality
This module consists of four units which will provide the user a basic knowledge of cancer as a disease.
Module 5: What is Cancer? This module consists of four units which will provide the user a basic knowledge of cancer as a disease. After completing this module, cancer abstractors will be able to: Define
Update on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
Hospital-Based Tumor Registry. Srinagarind Hospital, Khon Kaen University
Hospital-Based Tumor Registry Srinagarind Hospital, Khon Kaen University Statistical Report 2012 Cancer Unit, Faculty of Medicine Khon Kaen University Khon Kaen, Thailand Tel & Fax:+66(43)-202485 E-mail:
4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma
Chapter Sixteen Oncology bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o Combining Forms Prefixes and Suffixes Carcinogenesis anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Causes of cancer
NEOPLASMS C00 D49. Presented by Jan Halloran CCS
NEOPLASMS C00 D49 Presented by Jan Halloran CCS 1 INTRODUCTION A neoplasm is a new or abnormal growth. In the ICD-10-CM classification system, neoplastic disease is classified in categories C00 through
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
Pathology of lung cancer
Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
Tumor Patterns. Common Morphologic Patterns in Soft Tissue Tumors. Update on Lipomatous Tumors. MFH-like. Highly cellular spindle cell pattern
Common Morphologic Patterns in Soft Tissue Tumors John R. Goldblum, M.D. Chairman, Department of Anatomic Pathology The Cleveland Clinic Professor of Pathology Cleveland Clinic Lerner College of Medicine
日 本 病 理 学 会 中 国 四 国 支 部 学 術 集 会 ( 第 114 回 スライドカンファレンス) 診 断 投 票 結 果
日 本 病 理 学 会 中 国 四 国 支 部 学 術 集 会 ( 第 114 回 スライドカンファレンス) 診 断 投 票 結 果 平 成 26 年 6 月 14 日 高 知 大 学 医 学 部 臨 床 講 義 棟 第 3 講 義 室 S2509 頬 粘 膜 腫 瘍 *Speaker's diagnosis Solitary fibrous tumor 12 Solitary fibrous tumor
The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
Outline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
Table 2.2. Cohort studies of consumption of alcoholic beverages and cancer in special populations
North America Canada Canadian 1951 Schmidt & Popham (1981) 1951 70 9 889 alcoholic men, aged 15 years, admitted to the clinical service of the Addiction Research Foundation of Ontario between Death records
PROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
The develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD
TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD Victor E. Reuter, MD Memorial Sloan-Kettering Cancer Center reuterv@mskcc.org 66 th Annual Pathology Seminar California Society of Pathologists Short
CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
Oncology. Topic-Bile Duct Carcinoma. Topic-Adenocarcinoma, Lung. Topic-Hemangiosarcoma, Spleen and Liver
Topic-Adenocarcinoma, Lung Figure 1. Pulmonary adenocarcinoma. Figure 2. Pulmonary bronchiolar carcinoma. Figure 3. Pulmonary fibrosarcoma. Topic-Adenocarcinoma, Skin (Sweat Gland, Sebaceous) Figure 1.
- Slide Seminar - Endocrine pathology in non-endocrine organs. Case 11. Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa
- Slide Seminar - Endocrine pathology in non-endocrine organs Case 11 Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa Dept. of Pathology, Multimedica, Milan, Italy Dept. of Surgical and Morphological
Pathology Update THE ROLE OF IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF SOFT-TISSUE TUMORS
Pathology Update THE ROLE OF IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF SOFT-TISSUE TUMORS Carlos A. Muro-Cacho, MD, PhD Pathology Service, H. Lee Moffitt Cancer Center & Research Institute
C a nc e r C e nter. Annual Registry Report
C a nc e r C e nter Annual Registry Report 214 214 Cancer Registry Report Larraine A. Tooker, CTR Please note that the 214 Cancer Registry Annual Report is created in 214, but it reflects data on cases
New Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
Cancer and how your policy works. General & Medical
Cancer and how your policy works General & Medical This booklet, like others in our information book series are designed to help you understand the various aspects of General & Medical private healthcare
Lung Cancer. Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine
Lung Cancer Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine Alexandria, Egypt July 1-1 3, 2008 OBJECTIVES Describe and
NLSY79 ATTACHMENT 8: HEALTH CODES
NLSY79 ATTACHMENT 8: HEALTH CODES 1 GENERAL INFORMATION ON HEALTH CODES The health section of the NLS survey elicits health problems that limit the amount or kind of work the respondent can do. Those health
Grossing & Intraoperative Evaluation Boot Camp
AP RTC July 2011 Moffitt: HSW- 532 Zion: B2 Conf. Room MON TUES WED THURS FRI Grossing & Intraoperative Evaluation Boot Camp 4 5 6 Lymph node & general principles in gross pathology - Grossing principles
FRCPath Part 2 Histopathology Short Cases, autumn 2014
FRCPath Part 2 Histopathology Short Cases, autumn 2014 Commentary Case 1 Female age 52: palpable lesion, left breast Breast, fat necrosis. Average: 2.6/5 This case was chosen as a good example of fat necrosis
Diagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
MEDICAL POLICY POLICY TITLE
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): Effective Date: April 15, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND High dose chemotherapy (HDC) involves the administration
Description Code Recommendation Description Code. All natural death 001-799 IPH All natural death A00-R99
Natural death Description Code Recommendation Description Code All natural death 001-799 IPH All natural death A00-R99 Infectious and parasitic diseases 001-139 CDC, EUROSTAT, CBS & VG Infectious and parasitic
History. Female age 64. Tumour right kidney on scan. Partial nephrectomy. Tumour 18mm diameter.
FRCPath Part 2 Histopathology Examination Histology short cases Commentary. Case 1. History. Female age 64. Tumour right kidney on scan. Partial nephrectomy. Tumour 18mm diameter. Diagnosis: Angiomyolipoma
Number. Source: Vital Records, M CDPH
Epidemiology of Cancer in Department of Public Health Revised April 212 Introduction The general public is very concerned about cancer in the community. Many residents believe that cancer rates are high
Applications of immunohistology to non-heme tumor differential diagnosis R V Rouse 7/22/2014 http://surgpathcriteria.stanford.edu
Applications of immunohistology to non-heme tumor differential diagnosis R V Rouse 7/22/2014 http://surgpathcriteria.stanford.edu Table of Contents Page Undifferentiated panel 1 CK7/20 table 2 Breast carcinoma
Frozen Section Diagnosis
Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The
Disclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!
Disclosures Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! No Relevant Financial Relationships with Commercial Interests Syed Z. Ali, M.D. Syed Z. Ali, M.D. Associate Professor of
Immunohistochemistry in the Diagnosis of Metastatic Carcinoma of Unknown Primary Origin
Immunohistochemistry in the Diagnosis of Metastatic Carcinoma of Unknown Primary Origin Rodney T. Miller, M.D. Director of Immunohistochemistry ProPath Laboratory 1355 River Bend Drive Dallas, TX 75247-4915
Lessons from a consultation practice
Pitfalls in the Application of Immunohistochemistry in Diagnostic Pathology Lessons from a consultation practice Kevin O. Leslie, MD Professor and Consultant Mayo Clinic Arizona Scottsdale, Arizona Presenter
The term undifferentiated tumor has been used in reference
Undifferentiated Tumor True Identity by Immunohistochemistry Armita Bahrami, MD; Luan D. Truong, MD; Jae Y. Ro, MD, PhD Context. Undifferentiated tumor refers to a heterogeneous group of neoplasms with
THE CANCER CENTER 2013 ANNUAL REPORT CONTAINING 2012 STATISTICS
THE CANCER CENTER 2013 ANNUAL REPORT CONTAINING 2012 STATISTICS Northside Medical Center Cancer Committee Mission Statement It is the mission of the Cancer Committee to evaluate and monitor the care of
INDEX. Performance Improvement Program in Surgical Pathology SURVEYS 2012 AND ANATOMIC PATHOLOGY EDUCATION PROGRAMS
INDEX SURVEYS 2012 AND ANATOMIC PATHOLOGY EDUCATION PROGRAMS Performance Improvement Program in Surgical Pathology PIP CASE SUMMARY INDEX 1989-2012 Breast 89-17 Angiosarcoma 86% 89-37 Tubular adenoma 97%
REPORTABLE NEOPLASMS. Reportable List
to Based on FY2014 codes REPORTABLE NEOPLASMS and subcategory codes are shaded in grey and marked with an ^ Cells shaded in pink and marked with an *indicate the preferred code when a single code maps
Abstracts and References
Abstracts and References Soft Tissue Pathology Professor Cyril Fisher, Royal Marsden Hospital Learning points CD34 and CK positivity coexist in epithelioid sarcoma and epithelioid endothelial tumours.
How To Test For Cancer
Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion Syed Z. Ali, M.D. Professor of Pathology and Radiology The Johns Hopkins Hospital Baltimore, Maryland Diagnostic
DELRAY MEDICAL CENTER. Cancer Program Annual Report
DELRAY MEDICAL CENTER Cancer Program Annual Report Cancer Statistical Data From 2010 TABLE OF CONTENTS Chairman s Report....3 Tumor Registry Statistical Report Summary...4-11 Lung Study.12-17 Definitions
Cytokeratins and generel epithelial markers in tumour classification
Cytokeratins and generel epithelial markers in tumour classification 42, liver adenocarcinoma of unknown primary Colonrectum? Pancreas/biliary tract? Stomach? Lung? Ovary/endometrium? Mogens Vyberg, NordiQC
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
Friend for Life Cancer Support Network Annual Report 2010. Facing cancer, with someone who s been there
Friend for Life Cancer Support Network Annual Report 2010 Facing cancer, with someone who s been there This is wonderful support for those of us who are newly diagnosed with cancer. Our Mission To help
CHAPTER 4 Specific tumor sites (part 1)
CANCER REGISTRATION HANDBOOK CHAPTER 4 Specific tumor sites (part 1) Contents IV(1)-2 IV(1)-2 IV(1)-3 IV(1)-3 IV(1)-3 IV(1)-3 IV(1)-4 IV(1)-4 IV(1)-7 IV(1)-7 IV(1)-7 IV(1)-8 IV(1)-8 IV(1)-8 IV(1)-9 IV(1)-9
Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
Utility of immunohistochemistry in the diagnosis of bone tumors
Dr. M. Sailaja Review article Utility of immunohistochemistry in the diagnosis of bone tumors Sailaja M 1,* and Satish Rao I 1 1 Department of Laboratory Medicine, Krishna Institute of Medical sciences,
Pediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
The effect of the introduction of ICD-10 on cancer mortality trends in England and Wales
The effect of the introduction of ICD-10 on cancer mortality trends in Anita Brock, Clare Griffiths and Cleo Rooney, Offi ce for INTRODUCTION From January 2001 deaths in have been coded to the Tenth Revision
Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
Histopathology of Major Salivary Gland Neoplasms
Histopathology of Major Salivary Gland Neoplasms Sam J. Cunningham, MD, PhD Faculty Advisor: Shawn D. Newlands, MD, PhD Faculty Advisor: David C. Teller, MD The University of Texas Medical Branch, Department
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
Local Coverage Article: Drugs and Biologicals - Chemotherapeutic Agents (A52701)
Local Coverage Article: Drugs and Biologicals - Chemotherapeutic Agents (A52701) Contractor Information Contractor Name Cahaba Government Benefit Administrators, LLC Article Information General Information
page antibody Adipophilin (polyclonal) ALDH1A1 (44) c-myc (EP121) * Cadherin-17 (SP183) Cathepsin K (3F9)
New IHC Antibodies 2 Table of Contents page antibody 1 2 3 4 5 6 7 8 Adipophilin (polyclonal) ALDH1A1 (44) c-myc (EP121) * Cadherin-17 (SP183) Cathepsin K (3F9) Caveolin-1 (2297) CD13 (SP187) CD16 (SP175)
ENTERAL NUTRITION Policy/CPT ICD-10 ICD-10 Description ICD-9 ICD-9 Description EPA 870001100 N18.6 End stage renal disease 585.
ENTERAL NUTRITION Policy/CPT ICD-10 ICD-10 Description ICD-9 ICD-9 Description EPA 870001100 N18.6 End stage renal disease 585.6 End stage renal disease EPA 870001101 C00.0 Malignant neoplasm of external
190.25 - Alpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
The menstrual cycle Hypophysis
Normal endometrium Tumors of the uterine corpus by MB The endometrium comprises the zona functionalis zf (superficial two thirds) ) and the zona basalis zb (deep one third) The zf responds to hormonal
HADRON THERAPY FOR CANCER TREATMENT
HADRON THERAPY FOR CANCER TREATMENT Seminar presented by Arlene Lennox at Fermilab on Nov 21, 2003 CANCER STAGES LOCAL TUMOR REGIONAL METASTASIS SYSTEMIC DISEASE CANCER TREATMENT SURGERY RADIATION THERAPY
ORGAN SYSTEMS OF THE BODY
ORGAN SYSTEMS OF THE BODY DEFINITIONS AND CONCEPTS A. Organ a structure made up of two or more kinds of tissues organized in such a way that they can together perform a more complex function that can any
Measure Name: Low Back Pain Imaging Studies Measure Code: LBP Lab Data: N
Measure Name: Low Back Pain Imaging Studies Owner: NCQA (LBP) Measure Code: LBP Lab Data: N Rule Description: General Criteria Summary The percentage of patients 18-50 years of age who had a principal
Metastasis. Brookdale Hospital, Brooklyn, New York 11212, USA; 2 Cambridge, MA 02138, USA ma8080@gmail.com
Metastasis Ma Hongbao 1, Margaret Ma 2, Yang Yan 1 1 Brookdale Hospital, Brooklyn, New York 11212, USA; 2 Cambridge, MA 02138, USA ma8080@gmail.com Abstract: Cancer begins when cells in a part of the body
Something Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
Pleural and Chest Wall Tumors
Pleural and Chest Wall Tumors Ritu Gill, MD, MPH Dr. Ritu R. Gill Department t of Radiology Brigham and Women s Hospital Harvard Medical School CLASSIFICATION OF CHEST WALL TUMORS Primary neoplasm of chest
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
# Circuits relevant to cancer, related to known TFs.
# Circuits relevant to cancer, related to known TFs. # Final dataset of circuits where at least one gene has been annotated as relevant to cancer. # Circuits correspond to blocks separated by a symbol.
Immunohistochemistry in diagnostic pathology of tumors. Approach, benefits, limits and pitfalls
Aus dem Institut für Pathologie der Medizinischen Fakultät Charité Universitätsmedizin Berlin DISSERTATION Immunohistochemistry in diagnostic pathology of tumors. Approach, benefits, limits and pitfalls
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
PathMD: Board Review Letter TM
Questions 1. Mantle Cell Lymphoma is associated with which of the following: A. t(11;14) B. t(8;14) C. t(2;5) D. t(11;18) E. t(14;18) 2. A case of anaplastic large cell lymphoma (ALCL) with t(1;2) is stained
Oncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control
Oncology Objectives Describe the etiology and pathophysiological mechanisms of cancer Discuss medical and family history findings relevant to cancer Identify general signs and symptoms associated with
Notice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada achurg@mail.ubc.ca Notice of Faculty Disclosure In accordance with
Cancer Conferences 2008
2009 Annual Report Cancer Registry Report The Cancer Registry collects data on all cancer patients who were diagnosed and/or treated at East Alabama Medical Center. Diagnostic, therapeutic and outcome
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
Thyroid Transcription Factor-1 (TTF 1): protein expression is not exclusive to lung and thyroid tissue.
Thyroid Transcription Factor-1 (TTF 1): protein expression is not exclusive to lung and thyroid tissue. Scorer PW, Pinkney M, McIntosh GG. Leica Biosystems Newcastle Ltd, Balliol Business Park West, Benton
Multiple Primary and Histology Coding Rules
Multiple Primary and Histology Coding Rules January 10, 2008 National Cancer Institute Surveillance Epidemiology and End Results Program Bethesda, MD PLEASE NOTE This PDF of the 2007 Multiple Primaries
Nuno Morais 1 José António Moreira da Costa 2
Nuno Morais 1 José António Moreira da Costa 2 1 Neurosurgery Department, Hospital de Braga, Braga, Portugal 2 Private Practice, Clínica Neurológica e da Coluna Vertebral, Braga, Portugal Disclosure Funding
Practical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
Immunohistochemistry of clear cell tumours. What are clear cell tumours? Jan Klos 1
Immunohistochemistry of clear cell tumours J. Klos MD Department of Pathology Stavanger University Hospital Norway What are clear cell tumours? Multiple factors in etiology of clear cell changes: - technical
The Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
Primary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
How To Test For Cancer With A Blood Test
Histolab Products AB Eva Alströmer Jonas Falgén Helsingborg 7-8/10 2010 Table 1 Formalin Fixation Times and Estrogen Receptor Staining With 25 Minutes Antigen Retrieval Pretreatment Formalin Q-Score Difference
SEER SINQ s. Finalized March 2011
ized March 2011 : 20110067 First course treatment--heme & Lymphoid Neoplasms: Are the treatment guidelines in the "red book" still valid? See discussion. While I realize that the Hematopoietic Database
The Ontario Cancer Registry moves to the 21 st Century
The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
How CanCer becomes critical in the claims
How CanCer becomes critical in the claims arena Cancer is a disease in which cells in your body grow in an uncontrolled way and form a lump called a tumour. In a healthy individual cells grow and reproduce
CANCER COMMITTEE MEMBERS NORTHWESTERN LAKE FOREST HOSPITAL\ 2010
CANCER COMMITTEE MEMBERS NORTHWESTERN LAKE FOREST HOSPITAL\ 2010 Michael Cochran, MD Susan Balling R.N. Karline Peal RT Stephen Ganshirt M.D. Nancy Bulzoni Emily Rosecrans Joseph Imperato M.D Linda Dickson
3-F. Pathology of Mesothelioma
3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which
Cancer in Western Australia: Incidence and mortality 2003 and Mesothelioma 1960-2003
Cancer in Western Australia: Incidence and mortality 2003 and Mesothelioma 1960-2003 A report of the Western Australian Cancer Registry Health Data Collections, Information Collection and Management Department
at a critical moment Physician Suggestion Line...
Radiation Oncology Exceptional care at a critical moment When your patients require radiation therapy, they deserve the very best care available to them. The Department of Radiation Oncology provides exceptional
Local Coverage Determination (LCD): Immunohistochemistry (L34369)
Local Coverage Determination (LCD): Immunohistochemistry (L34369) Contractor Information Contractor Name CGS Administrators, LLC LCD Information Document Information LCD ID L34369 Original ICD9 LCD ID
A 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which